clinical trial · NCT04572854
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
C3GIC-MPGNRenal TransplantComplement 3 GlomerulopathyComplement 3 Glomerulopathy (C3G)Dense Deposit Disease (DDD)Membranoproliferative GlomerulonephritisMembranoproliferative Glomerulonephritis (MPGN)Pegcetacoplan
brief summary
This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.
started
Sep 7, 2021
primary completion
Feb 27, 2023
completion
Jan 20, 2026
last updated
Apr 21, 2026
official title
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol